Trials / NCT04312672
Long-term Follow-up Gene Therapy Study for RPGR- XLRP
Completed Observational Natural history / observational
- Sponsor
- MeiraGTx Ocular UK Ltd
- Treatment
- AAV5-hRKp.RPGR
- Gene
- RPGR
- Conditions
- X-Linked Retinitis Pigmentosa
- Ages
- 5 Years to no upper limit
- Enrollment
- 42 participants
- Started
- 2017-07-31
- Main results expected
- 2025-09-17
- Results posted
- Not yet
- Record last updated
- 2026-09-25
What the study is testing
This is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLRP caused by mutations in RPGR.
Where it runs
United Kingdom (2)
- Leeds Teaching Hospitals NHS Trust, Leeds
- Moorfields Eye Hospital, London
United States (3)
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
- Univ of Michigan Medical Center, Ann Arbor, Michigan
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania